{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:11:57Z","timestamp":1747149117712,"version":"3.40.5"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T00:00:00Z","timestamp":1650499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatol Commun"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Real\u2010world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real\u2010world outcomes with other first\u2010line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and followed them for 36\u00a0months prospectively. We analyzed switching patterns of antiviral therapy and treatment outcomes of TAF, tenofovir disoproxil fumarate (TDF), and entecavir therapy. For efficacy and safety, we analyzed a subset of patients with complete data at 24\u00a0months after switching to TAF or remaining on TDF or entecavir. Among 1037 enrollees, 889 patients were analyzed. The mean age was 52%, and 72% were hepatitis B e antigen\u2013negative. After enrollment, shifts in therapies were mostly in reduced use of TDF from 63% to 30% due to switching to TAF. Clinical parameters were compared at enrollment or initiation to measures at 24\u00a0months for patients remaining on TAF (187), TDF (229), or entecavir (181). At 24\u00a0months, a significantly higher portion of patients on TAF achieved hepatitis B virus (HBV) DNA \u2264\u200920\u2009IU\/ml (93% vs. 86%; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.012) and normalized alanine aminotransferase (ALT) (66% vs. 56%; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.031) with stable estimated glomerular filtration rates (eGFRs). However, a higher percentage of the patient with eGFR &lt;\u200960\u2009ml\/mi\/1.7\u00a0m<jats:sup>2<\/jats:sup> was observed in the TDF\u2010treated group (9% vs. 4%; <jats:italic toggle=\"yes\">p<\/jats:italic>\u00a0=\u00a00.010). In patients who remained on entecavir or TDF for 24\u00a0months, ALT and HBV\u2010DNA results did not differ significantly from baseline. Treatment of CHB in the United States has significantly shifted from TDF to TAF. Our data suggest that switching from TDF or entecavir to TAF may result in increased frequency of ALT normalization and potential clearance of viremia at the 24\u2010month time point.<\/jats:p>","DOI":"10.1002\/hep4.1964","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T09:07:10Z","timestamp":1650532030000},"page":"1881-1894","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["First\u2010line therapies for hepatitis B in the United States: A 3\u2010year prospective and multicenter real\u2010world study after approval of tenofovir alefenamide"],"prefix":"10.1097","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-6688","authenticated-orcid":false,"given":"Calvin Q.","family":"Pan","sequence":"first","affiliation":[{"name":"Beijing Ditan Hospital,Capital Medical University,Beijing,China"},{"name":"NYU Langone Health,NYU Grossman School of Medicine,New York,New York,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nezam H.","family":"Afdhal","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center,Boston,Massachusetts,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor","family":"Ankoma\u2010Sey","sequence":"additional","affiliation":[{"name":"Liver Associates of Texas, P.A.,Houston,Texas,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho","family":"Bae","sequence":"additional","affiliation":[{"name":"St. Vincent Medical Center,Asian Pacific Liver Center,Los Angeles,California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Curry","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center,Boston,Massachusetts,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Dieterich","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine,New York,New York,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Frazier","sequence":"additional","affiliation":[{"name":"Liver Wellness Center,Little Rock,Arkansas,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Frick","sequence":"additional","affiliation":[{"name":"Trio Health Analytics,Louisville,Colorado,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hie\u2010Won","family":"Hann","sequence":"additional","affiliation":[{"name":"Thomas Jefferson University Hospital,Philadelphia,Pennsylvania,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine,Stanford,California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kwo","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine,Stanford,California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Milligan","sequence":"additional","affiliation":[{"name":"Trio Health Analytics,Louisville,Colorado,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron J.","family":"Tong","sequence":"additional","affiliation":[{"name":"Huntington Medical Research Institutes,Pasadena,California,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[{"name":"University of Pennsylvania,Philadelphia,Pennsylvania,USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,21]]},"reference":[{"key":"hep41964-bib-0001-20241129","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cgh.2014.06.028","article-title":"Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype","volume":"13","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41964-bib-0002-20241129","first-page":"36","article-title":"Natural history and clinical consequences of hepatitis B virus infection","volume":"2","year":"2005","journal-title":"Int J Med Sci"},{"key":"hep41964-bib-0003-20241129","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/jvh.12670","article-title":"Long\u2010term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy","volume":"24","year":"2017","journal-title":"J Viral Hepat"},{"key":"hep41964-bib-0004-20241129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep41964-bib-0005-20241129","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg\u2010positive chronic hepatitis B","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"hep41964-bib-0006-20241129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg\u2010negative chronic hepatitis B","volume":"354","year":"2006","journal-title":"N Engl J Med"},{"key":"hep41964-bib-0007-20241129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg\u2010positive chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep41964-bib-0008-20241129","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg\u2010negative chronic hepatitis B virus infection: a randomised, double\u2010blind, phase 3, non\u2010inferiority trial","volume":"1","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"hep41964-bib-0009-20241129","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"hep41964-bib-0010-20241129","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real\u2010world evidence\u2014what is it and what can it tell us?","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"hep41964-bib-0011-20241129","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cpt.857","article-title":"When and how can real world data analyses substitute for randomized controlled trials?","volume":"102","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"hep41964-bib-0012-20241129","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jvh.12358","article-title":"Long\u2010term entecavir or tenofovir disoproxil fumarate therapy in treatment\u2010naive chronic hepatitis B patients in the real\u2010world setting","volume":"22","year":"2015","journal-title":"J Viral Hepat"},{"key":"hep41964-bib-0013-20241129","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1007\/s10620-015-4027-8","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3\u2010year, prospective, real\u2010world study in France","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"hep41964-bib-0014-20241129","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10620-015-3960-x","article-title":"Effectiveness and safety of tenofovir disoproxil fumarate in chronic hepatitis B: a 3\u2010year prospective field practice study in Germany","volume":"61","year":"2016","journal-title":"Dig Dis Sci"},{"key":"hep41964-bib-0015-20241129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3851\/IMP3205","article-title":"Real\u2010world evidence for nucleoside\/nucleotide analogues in a 5\u2010year multicentre study of antiviral\u2010naive chronic hepatitis B patients in China: 52\u2010week results","volume":"23","year":"2018","journal-title":"Antivir Ther"},{"key":"hep41964-bib-0016-20241129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3904\/kjim.2016.111","article-title":"Large\u2010scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B","volume":"33","year":"2018","journal-title":"Korean J Intern Med"},{"key":"hep41964-bib-0017-20241129","article-title":"Seven\u2010year treatment outcome of entecavir in a real\u2010world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"hep41964-bib-0018-20241129","article-title":"Real\u2010world study on clinical outcomes of nucleos(t)ide analogues antiviral therapy in patients with chronic hepatitis B","volume":"147","year":"2019","journal-title":"Epidemiol Infect"},{"key":"hep41964-bib-0019-20241129","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2147\/IDR.S185120","article-title":"Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus\u2010related cirrhosis: a real\u2010world prospective multicenter cohort study","volume":"12","year":"2019","journal-title":"Infect Drug Resist"},{"key":"hep41964-bib-0020-20241129","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jvh.12736","article-title":"Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: a community\u2010based real\u2010world study","volume":"24","year":"2017","journal-title":"J Viral Hepatol"},{"key":"hep41964-bib-0021-20241129","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.13440","article-title":"Entecavir safety and effectiveness in a national cohort of treatment\u2010naive chronic hepatitis B patients in the US\u2014the ENUMERATE study","volume":"43","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41964-bib-0022-20241129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10620-018-5281-3","article-title":"A comparison between community and academic practices in the USA in the management of chronic hepatitis B patients receiving entecavir: results of the ENUMERATE study","volume":"64","year":"2019","journal-title":"Dig Dis Sci"},{"key":"hep41964-bib-0024-20241129","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","year":"2006","journal-title":"Hepatology"},{"key":"hep41964-bib-0025-20241129","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.ajkd.2010.11.007","article-title":"Comparison of the CKD Epidemiology Collaboration (CKD\u2010EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP)","volume":"57","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"hep41964-bib-0026-20241129","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH\u2010B): development and validation of a predictive score","volume":"12","year":"2011","journal-title":"Lancet Oncol"},{"issue":"67","key":"hep41964-bib-0027-20241129","first-page":"370","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"2017","year":"2017","journal-title":"J Hepatol"},{"key":"hep41964-bib-0028-20241129","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.14577","article-title":"An expert consensus for the management of chronic hepatitis B in Asian Americans","volume":"47","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"hep41964-bib-0029-20241129","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u2009weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","year":"2018","journal-title":"J Hepatol"},{"key":"hep41964-bib-0030-20241129","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/liv.14482","article-title":"Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B","volume":"40","year":"2020","journal-title":"Liver Int"},{"key":"hep41964-bib-0031-20241129","article-title":"Clinical characteristics of hepatitis B virus patients after switching to tenofovir alafenamide fumarate: a retrospective observational study","volume":"12","year":"2020","journal-title":"Cureus"},{"key":"hep41964-bib-0032-20241129","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1111\/jgh.14686","article-title":"Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate","volume":"34","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"hep41964-bib-0033-20241129","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/jmv.25644","article-title":"Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate","volume":"92","year":"2020","journal-title":"J Med Virol"},{"key":"hep41964-bib-0034-20241129","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1016\/j.cgh.2020.03.001","article-title":"Persistent low level of hepatitis B virus promotes fibrosis progression during therapy","volume":"18","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"hep41964-bib-0035-20241129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low\u2010level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","year":"2017","journal-title":"Hepatology"},{"key":"hep41964-bib-0036-20241129","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier alanine aminotransferase normalization during antiviral treatment is independently associated with lower risk of hepatocellular carcinoma in chronic hepatitis B","volume":"115","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"hep41964-bib-0037-20241129","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on\u2010treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","year":"2018","journal-title":"J Hepatol"}],"container-title":["Hepatology Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep4.1964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep4.1964","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1964","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T13:04:03Z","timestamp":1732885443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep4.1964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,21]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep4.1964","relation":{},"ISSN":["2471-254X","2471-254X"],"issn-type":[{"type":"print","value":"2471-254X"},{"type":"electronic","value":"2471-254X"}],"subject":[],"published":{"date-parts":[[2022,4,21]]},"assertion":[{"value":"2021-11-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}